The companys research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions. The target has been validated in in-vivo models & human pathological material. Global Markets Directs, Santaris Pharma A/S - Product Pipeline Review - 2014, provides an overview of the Santaris Pharma A/Ss pharmaceutical research and development focus. Privacy Policy CiVi's innovative pipeline includes CIVI 007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of cardiovascular disease. Swiss Therapeutics company developing therapies to treat severe neurological disorders. In addition to miravirsen, Santaris Pharma A/S has a robust product pipeline targeting mRNAs and microRNAs both internally as well as in partnerships and collaborations with . - The loss after tax realised in the 2nd quarter of 2009 was 21,6m DKK (2,9m EUR) compared to 29,8m DKK (4,0m EUR) in the 2nd quarter of 2008. Patent number: 8906871. Date of Patent: December 9, 2014. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. Dog kom selskabet i gr med en opdateret pipeline Hanne Damgaard Jensen synes godt om dette . Zealand Pharma is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. After M&A, selloffs, cost cuts and therapeutic rejigs, the companies on this list may largely wear the same names, but none entered it looking exactly .. Bioventus is a global leader of innovations for active healing and surgical orthobiologics with a comprehensive portfolio of clinically efficacious and cost-effective solutions for patients . Products on the veterinary market includes the adjuvant for the leading horse influenza vaccine. Santaris Pharma A/S Advances a Second Drug from Its. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. These so-called Spiegelmers (the German word Spiegel means mirror) are highly specific for the pharmacologically relevant target for which they were selected. The popularity score combines profile views, clicks and the number of times the company appears in search results. Phase 1 clinical study to assess safety and tolerability of SPC4955, a drug inhibiting synthesis of apolipoprotein B (apoB), a major protein component involved in the . [2] Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine. WhatsApp acquired by Facebook). Zealand Pharma is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. LinkedIn Roche Group Diagnostics pipeline. MedChemComm View Article Online Published on 01 August 2014. Commun., 2014, 5, 1454 Vivek K. Sharma,a Raman K. Sharmab and Sunil K. Singh*c There has been an upsurge in the number of clinical trials . Vaccines for veterinary and human use. The core therapeutic focus of our company is obesity, Type II diabetes / metabolic syndrome, inflammatory diseases, and organ protection in severe cardiovascular diseases such as . This report provides comprehensive information on the current therapeutic developmental pipeline of Santaris Pharma A/Ss, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. You must have cookies enabled to login US-based Healthtech company providing remote patient monitoring solutions for COPD patients. Santaris Pharma is a biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. Santaris Pharma 2007 - 2009 2 r. COPENHAGEN, Denmark | November 10, 2008 | Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. [3] Resistentia Pharmaceuticals AB, a biotechnology company founded in 1998, developing an allergy vaccine with human as well as veterinary applications. Submit a Company in addition to miravirsen, santaris pharma a/s has a robust product pipeline targeting mrnas and micrornas both internally as well as in partnerships and collaborations with miragen therapeutics (cardiovascular diseases), shire plc (rare genetic disorders), pfizer (undisclosed therapeutic areas), glaxosmithkline (viral disease) and enzon features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Since Gilde invested in Santaris Pharma, the company has advanced its product pipeline through the clinic and signed commercial collaboration agreements with GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Roche and Shire. Santaris Pharma A/S - Product Pipeline Review - 2014 Published by Global Markets Direct at researchbeam.com [Report Price $1500] 39 Pages help@researchbeam.com +1-971-202-1575 | Toll Free: +1 (800)910-6452 Santaris Pharma A/S - Product Pipeline Review - 2014. Santaris' pipeline of RNAi - or ' gene silencing ' - drugs are based on its Locked Nucleic Acid (LNA) platform and its lead candidate is miravirasen, a novel hepatitis C treatment in phase II trials. Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, announced that it has advanced a second drug from its cardiometabolic programme, SPC4955 into phase I clinical trials, for the treatment of high cholesterol. By using its proprietary Locked Nucleic Acid (:LNA) platform and tissue-targeting expertise, Santaris Pharma is developing a diverse pipeline of LNA therapeutics that influence the production or . HISTORICAL PERFORMANCE: From 2014-2019 Merck's stock has grown at 1.3x the rate of AbbVie. - The report provides brief overview of Santaris Pharma A/S including business description, key information and facts, and its locations and subsidiaries, - The report reviews current pipeline of Santaris Pharma A/Ss human therapeutic division and enlists all their major and minor projects, - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones, - Special feature on out-licensed and partnered product portfolio, - The report summarizes all the dormant and discontinued pipeline projects, - Latest news and deals relating to the Santaris Pharma A/Ss pipeline products, - Evaluate Santaris Pharma A/Ss strategic position with total access to detailed information on its product pipeline, - Assess the growth potential of Santaris Pharma A/S in its therapy areas of focus, - Identify new drug targets and therapeutic classes in the Santaris Pharma A/Ss R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas, - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps, - Develop strategic initiatives by understanding the focus areas of Santaris Pharma A/S and exploit collaboration and partnership opportunities, - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage, - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Santaris Pharma A/S, - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope, - Explore the dormant and discontinued projects of Santaris Pharma A/S and identify potential opportunities in those areas, - Avoid Intellectual Property Rights related issues, Pharma Pipeline Review - Market Research Reports, Santaris Pharma A/S - Product Pipeline Review - 2014. Santaris Pharma has pioneered its proprietary Locked Nucleic Acid (LNA) platform that has contributed to an emerging era of RNA-targeting therapeutics. PDF. The vaccine would be safer, easier to administer and more cost effective than other potential drug candidates currently under development. About Santaris Pharma. Continue reading on Roche.com: Locked Nucleic Acid (LNA) Platform Resistentia Pharmaceuticals ABSwedenDeadpoolResistentia Pharmaceuticals AB, a biotechnology company founded in 1998, developing an allergy vaccine with human as well as veterinary applications. Since Gilde invested in Santaris Pharma, the company has advanced its product pipeline through the clinic and signed commercial collaboration agreements with GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Roche and Shire. Santaris Pharma has pioneered its proprietary Locked Nucleic Acid (LNA) platform that has contributed to an emerging era of RNA-targeting therapeutics. You can follow this company for updates by clicking here. The core therapeutic focus of our company is obesity, Type II diabetes / metabolic syndrome, inflammatory diseases, and organ protection in severe cardiovascular diseases such as myocardial infarction and post-surgical organ failure. Contact Us Santaris Pharma unveiled its newest microRNA therapeutic program this week having acquired intellectual property from Massachusetts General Hospital related to the use of miR-33 as a target for cardiovascular disorders including hypercholesterolemia. Action Pharma A/S is a clinical stage biopharmaceutical company founded in 2000 and located in Denmark with offices and laboratories in Aarhus and Copenhagen. In addition to miravirsen, Santaris Pharma A/S has a robust product pipeline targeting mRNAs and microRNAs both internally as well as in partnerships and collaborations with miRagen Therapeutics . [3] Name of the organization that made the acquisition, Total amount raised across all funding rounds, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Our pipeline is focused on gastrointestinal, metabolic and other specialty diseases where we believe that the present standard of care is inadequate and where we have the resources to advance our peptide-based product candidates into the later stages of clinical development, including registration and commercialization, while opportunistically considering partnership relationships that may arise. Data from a phase II study has been published as well [96]. /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted. Products on the veterinary market includes the adjuvant for the leading horse influenza vaccine. We are currently in Phase 1/2 trials with our epigenetic drug, SP-2577, and in IND-enabling studies with SP-3164, a targeted protein degrader. This research strategy is generating a new clinical programme every year and continues to yield novel and proprietary drug targets, key to a more effective development of novel therapies. Santaris Pharma A/S advances a second drug from its cardiometabolic program, SPC4955, inhibiting apoB, into Phase 1 clinical trials for the treatment of high cholesterol. Access Full Search Results with a Business Account or On Demand Pass, About Us capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. +45 4517 9819 km@santaris.com Henrik Stage, Vice-President & CFO, Santaris Pharma A/S, Copenhagen, Denmark. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Santaris Pharma is using LNA to make novel, highly potent and stable RNA Antagonists. Associated sectors: Pharmaceuticals; Life sciences; Life Sciences - Pharma; Biotech; Life Science; Biotechnology; Healthcare - Drug development; Biopharmaceuticals; Healthtech; Healthcare; Life Sciences Companies - Drug Discovery and Development; Action PharmaDenmarkAcquiredAction Pharma A/S is a clinical stage biopharmaceutical company founded in 2000 and located in Denmark with offices and laboratories in Aarhus and Copenhagen. "HIF-1 alpha, as a target, has caught the imagination of the medical community for many years," Orum said. Chem. Active, Closed, Last funding round type (e.g. The core therapeutic focus of our company is obesity, Type II diabetes / metabolic syndrome, inflammatory diseases, and organ protection in severe cardiovascular diseases such as myocardial infarction and post-surgical organ failure. This report provides comprehensive information on the current therapeutic developmental pipeline of Santaris Pharma A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism . Contact us at the Consulting WP office nearest to you or submit a business inquiry online. We have three endocrinology rare disease product candidates in clinical development, and a pipeline of oncology candidates closely following. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the companys proprietary LNA chemistry with its highly specialized and targeted drug development. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. santaris pharma a/s has a robust product pipeline based on its proprietary lna technology including mrna and microrna drug discovery and development partnerships and collaborations with shire (rare genetic disorders), wyeth, now part of pfizer, (delivery of lead candidates against up to ten targets), glaxosmithkline (four viral disease drug
Cumulonimbus Calvus Height, Salesforce Cpq Roles And Responsibilities, Believe Crossword Clue 7 Letters, Human Benchmark Verbal Memory World Record, Phifertex Plus Mesh Fabric, West Valley City New Business List, Fire Emblem: Three Hopes, Lying On Social Media Statistics,
